Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to 0.59.

  • Tg Therapeutics' Equity Ratio rose 8066.02% to 0.59 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.59, marking a year-over-year increase of 8066.02%. This contributed to the annual value of 0.38 for FY2024, which is 2095.78% down from last year.
  • As of Q3 2025, Tg Therapeutics' Equity Ratio stood at 0.59, which was up 8066.02% from 0.39 recorded in Q2 2025.
  • Tg Therapeutics' Equity Ratio's 5-year high stood at 0.81 during Q1 2021, with a 5-year trough of 0.14 in Q1 2023.
  • Over the past 5 years, Tg Therapeutics' median Equity Ratio value was 0.46 (recorded in 2022), while the average stood at 0.48.
  • As far as peak fluctuations go, Tg Therapeutics' Equity Ratio surged by 620889.79% in 2021, and later tumbled by 7527.89% in 2023.
  • Over the past 5 years, Tg Therapeutics' Equity Ratio (Quarter) stood at 0.62 in 2021, then tumbled by 51.55% to 0.3 in 2022, then soared by 60.9% to 0.49 in 2023, then dropped by 20.96% to 0.38 in 2024, then soared by 53.9% to 0.59 in 2025.
  • Its Equity Ratio stands at 0.59 for Q3 2025, versus 0.39 for Q2 2025 and 0.36 for Q1 2025.